Please provide the clinical trial details so I can create a fitting title.

About 15% of adults worldwide perceive a persistent ringing, buzzing, or hissing sound that isn’t there. For roughly 20% of those with tinnitus, the experience is more than a mild nuisance; it causes significant distress and reduces quality of life. A new observational study in Belgium aims to measure a specific tool against this distress: the integrated noise generator in modern hearing aids. This trial will assess if this ‘Tinnitus-feature’ in newer Sonova hearing aids provides a measurable clinical benefit during routine use, especially for a group often left out of research—those with severe to profound hearing loss.

How the Trial Will Measure Real-World Benefit

The study is an observational trial. This means researchers are not assigning an intervention but measuring outcomes from patients who are already using the specific technology in their standard care. It will enroll up to 170 participants, identified both retrospectively and prospectively through a participating clinical site in Belgium.

All participants must already be users of at least one Sonova-manufactured hearing aid with its Tinnitus-feature—a built-in noise generator—activated for a minimum of 12 weeks. The primary tool for measuring success is the Tinnitus Functional Index (TFI), a validated questionnaire that assesses the impact of tinnitus across multiple life domains. A secondary measure is a simple Numerical Rating Scale (NRS) for tinnitus annoyance. Participants will complete these assessments to track any changes over time, providing data on the feature’s effectiveness in a routine clinical setting.

Who Can Participate in the Study?

The trial has clear criteria to define its participant group. Eligible individuals must be 18 or older and have experienced chronic tinnitus for at least six months. They must already be using the Tinnitus-feature on their Sonova hearing aids and have reported a baseline annoyance level of at least 3 on a 0-10 NRS scale. A significant aspect of the eligibility is the explicit inclusion of individuals with severe to profound hearing loss, aiming to address a known evidence gap. The main exclusion criterion is pulsatile tinnitus, a rarer form that often has a vascular origin and requires a different diagnostic approach.

The Science Behind Sound and Tinnitus Management

Hearing loss is a major risk factor for tinnitus, with theories suggesting the brain increases gain in the auditory system to compensate for lost input, leading to the perception of phantom sounds. This link is why clinical guidelines, such as those cited by Langguth et al. (2023), recommend hearing aids as a first-line therapeutic option. Amplifying external sound can help mask tinnitus and reduce the neural contrast between the tinnitus signal and silence.

Sound therapy, which includes the use of noise generators, is a long-established management strategy. The principle is to provide a neutral, external sound that can make the tinnitus less prominent or bothersome, a process often described as partial masking or habituation. A prior randomized controlled trial demonstrated the clinical efficacy of this feature in older Sonova hearing aid models. The current study, led by Sonova AG, seeks to extend that evidence to newer device generations and more severe hearing loss profiles.

Current Status and Potential Impact

As of the latest update, this trial’s status is listed as NOT_YET_RECRUITING. The protocol has received approval from a local Ethics Committee, and the participating clinical site is preparing to identify and enroll eligible subjects.

For patients, the outcomes of this study could offer more concrete, real-world data supporting the use of modern hearing aids with integrated sound therapy. If positive, the findings may encourage more audiologists to consider and activate these features for suitable candidates, particularly those with significant hearing loss who might benefit from a combined amplification and sound therapy solution. For the field, generating robust evidence on specific device features helps move tinnitus management toward more personalized and evidence-based protocols. Success in the severe-to-profound hearing loss cohort would be particularly valuable, as it addresses an unmet need in a patient population that struggles with limited treatment options.

This article is for informational purposes only. Consult a qualified professional for personalised advice.

Source:
Clinical Benefit of Hearing Aid Tinnitus Feature on Tinnitus-Related Annoyance in Tinnitus Patients in Belgium (ClinicalTrials.gov: NCT07711249)